Iżrael - Ebrajk - Ministry of Health

ferring pharmaceuticals ltd - menotrophin - אבקה וממס להכנת תמיסה להזרקה - menotrophin 600 iu - human menopausal gonadotrophin - human menopausal gonadotrophin - sterility in females with hypo or normogonadotropic ovarian insufficiency : stimulation of follicle growth. sterility in males with hypo or normogonadotropic hypogonadism: in combination with hcg to spermatogenesis.

Iżrael - Ebrajk - Ministry of Health

ferring pharmaceuticals ltd - menotrophin - אבקה וממס להכנת תמיסה להזרקה - menotrophin 1200 iu - human menopausal gonadotrophin - human menopausal gonadotrophin - sterility in females with hypo or normogonadotropic ovarian insufficiency: stimulation of follicle growth. sterility in males with hypo or normogonadotropic hypogonadism: in combination with hcg to spermatogenesis

Iżrael - Ebrajk - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Iżrael - Ebrajk - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Iżrael - Ebrajk - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Iżrael - Ebrajk - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Iżrael - Ebrajk - Ministry of Health

פישר מעבדות פרמצבטיות בעמ - הגנה משמש

Iżrael - Ebrajk - Ministry of Health

פישר מעבדות פרמצבטיות בעמ - הגנה משמש

Iżrael - Ebrajk - Ministry of Health

פישר מעבדות פרמצבטיות בעמ - םינפ יוקינ

Iżrael - Ebrajk - Ministry of Health

פישר מעבדות פרמצבטיות בעמ - קרם לילה